家族性非髓样甲状腺癌与散发性分化型甲状腺癌患者无进展生存期的比较
这项纵向回顾性队列研究纳入65例家族性非髓样甲状腺癌(FNMTC)患者和170例散发性分化型甲状腺癌(sDTC)患者,按年龄、性别、ATA复发风险分层、初始手术范围和诊断日期1:3匹配。中位随访约4.73-5.83年,两组疾病进展率无显著差异,无进展生存期(PFS)无差异,且与ATA复发风险分层和性别相关。结论提示FNMTC对标准治疗的反应性与sDTC相当,管理应与DTC标准一致以避免过度治疗。
要点
- FNMTC与sDTC两组PFS无差异(p=0.56),疾病进展率分别为15.4%和18.2%(p=0.61)。
- PFS与ATA复发风险分层相关:高风险vs低风险HR 9.2(95%CI 2.67-31.85,p<0.001)。
- PFS与性别相关:男性vs女性HR 2.5(95%CI 1.11-5.6,p=0.026)。
核心结论
- FNMTC与sDTC患者PFS无差异,提示对标准治疗的反应性相当。
- 作者认为FNMTC的管理应与DTC的标准治疗保持一致,以避免对FNMTC的过度治疗。
研究设计与样本
- 纵向回顾性队列研究,FNMTC定义为至少两名一级亲属患DTC。
- FNMTC患者按年龄、性别、ATA复发风险分层、初始手术范围和诊断日期以1:3比例与sDTC匹配。
- 研究人群为65例FNMTC和170例sDTC患者。
主要发现
- FNMTC中位随访4.73(2.87-10.27)年,sDTC中位随访5.83(2.33-10.79)年(p=0.76)。
- FNMTC肿瘤更小(1.20±0.96 vs 1.89±1.51 cm,p<0.01),阳性淋巴结更少(范围0-13 vs 0-38,p=0.009)。
- 因持续/复发疾病行重复颈部手术的比例:FNMTC 13.8%(9/65)vs sDTC 17.7%(30/170)(p=0.48)。
- 放射性碘治疗剂量两组无差异(104 [100-149] vs 106 [76-160] mCi,p=0.82)。
- 随访期间疾病进展:FNMTC 15.4% vs sDTC 18.2%(p=0.61);PFS两组无差异(p=0.56)。
临床怎么用
- 作者认为FNMTC的管理应与DTC的标准治疗保持一致,以避免过度治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Familial non-medullary thyroid carcinoma (FNMTC) accounts for approximately 9% of differentiated thyroid cancer (DTC). There is conflicting data on the FNMTC aggressiveness compared with sporadic DTC (sDTC), leading to usually more extensive therapy applied for FNMTC, given its autosomal dominant genetic background. This study aimed to compare the progression-free survival (PFS) in patients with FNMTC and sDTC treated with standard therapy. Methods: This longitudinal retrospective cohort study included patients with FNMTC, defined as at least two first-degree relatives affected by DTC. FNMTC patients were matched with sDTC in a 1:3 ratio based on age, sex, American Thyroid Association recurrence risk stratification (ATA-R), extent of initial surgery, and diagnosis date. The primary outcome was PFS. Kaplan-Meier curves were used to compare PFS between the groups, and the Cox proportional hazards model was used to assess confounders. Results: From 95 affected FNMTC patients, 30 were excluded due to lack of follow-up data. The study population consisted of 65 FNMTC and 170 sDTC patients, with a median follow-up of 4.73 (2.87-10.27) years for FNMTC and 5.83 (2.33-10.79) years for sDTC (p = 0.76). There was 100% matching for ATA-R, sex, surgery type, and year of surgery and a satisfactory matching for age (43.12 ± 15.11 vs. 42.76 ± 12.46 years, p = 0.85). FNMTC exhibited a smaller tumor size (1.20 ± 0.96 vs. 1.89 ± 1.51 cm, p < 0.01) and fewer positive lymph nodes (range 0-13 vs. 0-38, p = 0.009) at presentation. The rate of repeated neck surgeries for persistent/recurrent disease was comparable between the groups: 13.8% (9/65) for FNMTC vs. 17.7% (30/170) for sDTC (p = 0.48). There was no difference in radioactive iodine (RAI) therapy dosage between the groups (104 [100-149] vs. 106 [76-160] mCi, p = 0.82). During follow-up, 15.4% of FNMTC and 18.2% of sDTC patients experienced disease progression (p = 0.61). PFS was non-different between groups (p = 0.56) and was associated with ATA-R (high vs. low hazard ratio [HR]: 9.2, confidence interval [CI]: 2.67-31.85, p < 0.001) and sex (male vs. female, HR: 2.5, CI: 1.11-5.6, p = 0.026). Conclusions: No difference in PFS between FNMTC and sDTC patients suggests comparable responsiveness to standard therapy. Therefore, the management of FNMTC should align with the standard of care for DTC to avoid overtreatment of FNMTC.
引用
- Chuki E, Behairy N, Auh S, et al. Comparison of Progression-Free Survival in Familial Non-Medullary Thyroid Cancer and Sporadic Differentiated Thyroid Cancer Patients. Thyroid. 2025. PMID: 40392709. doi:10.1089/thy.2024.0588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。